| Item Type | Name |
|
Concept
|
Gastrointestinal Diseases
|
|
Academic Article
|
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
|
|
Academic Article
|
Infliximab in Crohn's disease: first anniversary clinical experience.
|
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
|
Academic Article
|
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
|
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
|
Academic Article
|
Safety first: messages from Digestive Disease Week 2006.
|
|
Academic Article
|
Emerging biologic therapies in inflammatory bowel disease.
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Moving ahead or falling behind?
|
|
Academic Article
|
The ethics of phase I trials of biologic agents.
|
|
Academic Article
|
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
|
|
Academic Article
|
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
|
|
Academic Article
|
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
|
|
Academic Article
|
Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions.
|
|
Academic Article
|
Practical application of anti-TNF therapy for luminal Crohn's disease.
|
|
Academic Article
|
What to take from TREAT?
|
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
|
Academic Article
|
Review article: safety of infliximab in clinical trials.
|
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
|
Academic Article
|
AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study.
|
|
Academic Article
|
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
|
|
Academic Article
|
Aminosalicylates for induction of remission or response in Crohn's disease.
|
|
Academic Article
|
Optimizing pharmacologic management of inflammatory bowel disease.
|
|
Academic Article
|
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
|
|
Academic Article
|
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
|
|
Academic Article
|
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events.
|
|
Academic Article
|
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
|
|
Academic Article
|
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.
|
|
Academic Article
|
The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease.
|